Stille AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000998650
SEK
189.50
0.5 (0.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.03

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 31.89%

 
3

The company has declared negative results in Mar'2025 after 4 consecutive positive quarters

4

With ROE of 7.46%, it has a fair valuation with a 2.54 Price to Book Value

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,577 Million (Small Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.20

stock-summary
Return on Equity

5.91%

stock-summary
Price to Book

2.28

Revenue and Profits:
Net Sales:
125 Million
(Quarterly Results - Jun 2025)
Net Profit:
10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.4%
0%
-15.4%
6 Months
-11.86%
0%
-11.86%
1 Year
-8.01%
0%
-8.01%
2 Years
41.42%
0%
41.42%
3 Years
55.33%
0%
55.33%
4 Years
29.79%
0%
29.79%
5 Years
112.92%
0%
112.92%

Stille AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
31.89%
EBIT Growth (5y)
41.13%
EBIT to Interest (avg)
9.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.82
Tax Ratio
18.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.21%
ROE (avg)
9.60%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
2.54
EV to EBIT
23.59
EV to EBITDA
17.86
EV to Capital Employed
3.02
EV to Sales
2.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.79%
ROE (Latest)
7.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.56% vs -19.09% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -31.51% vs -2.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "124.70",
          "val2": "129.30",
          "chgp": "-3.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "24.90",
          "val2": "24.80",
          "chgp": "0.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "4.80",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.00",
          "val2": "14.60",
          "chgp": "-31.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "137.10%",
          "val2": "135.70%",
          "chgp": "0.14%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 93.29% vs 19.73% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 118.80% vs -2.56% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "570.00",
          "val2": "294.90",
          "chgp": "93.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "136.50",
          "val2": "62.00",
          "chgp": "120.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.00",
          "val2": "10.10",
          "chgp": "-50.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "58.20",
          "val2": "26.60",
          "chgp": "118.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "161.00%",
          "val2": "161.70%",
          "chgp": "-0.07%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
124.70
129.30
-3.56%
Operating Profit (PBDIT) excl Other Income
24.90
24.80
0.40%
Interest
0.00
4.80
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
10.00
14.60
-31.51%
Operating Profit Margin (Excl OI)
137.10%
135.70%
0.14%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -3.56% vs -19.09% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -31.51% vs -2.67% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
570.00
294.90
93.29%
Operating Profit (PBDIT) excl Other Income
136.50
62.00
120.16%
Interest
5.00
10.10
-50.50%
Exceptional Items
-24.10
0.00
Consolidate Net Profit
58.20
26.60
118.80%
Operating Profit Margin (Excl OI)
161.00%
161.70%
-0.07%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 93.29% vs 19.73% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 118.80% vs -2.56% in Dec 2023

stock-summaryCompany CV
About Stille AB stock-summary
stock-summary
Stille AB
Pharmaceuticals & Biotechnology
Stille AB is a Sweden-based company engaged in the development, manufacture, and marketing of technical medical equipment. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.
Company Coordinates stock-summary
Company Details
Ekbacken 11 , TORSHAELLA None : 644 30
stock-summary
Tel: 46 8 58858000
stock-summary
Registrar Details